Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Apr 15, 2010 (Vol. 30, No. 8)

Strategies to Improve Biomarker Successes

Collaboration Is Essential to Advance Field and Improve Drug Development and Patient Care

  • Consortium

    The Biomarkers Consortium is a partnership of the Foundation for the National Institutes of Health (FNIH) that brings together the resources of NIH, FDA, the pharmaceutical industry, nonprofit organizations, and academic medical research centers to develop and qualify biomarkers that support more effective therapeutic development and patient care.

    The Consortium “helps qualify biomarkers and validate related analytical platforms in a precompetitive context,” says David Wholley, director. “There is a clear need to normalize and standardize our approach to biomarkers and underlying technologies across a therapeutic class or a common platform, such as the use of specific imaging modalities for diagnosis or to assess response to treatment. And, consensus across all stakeholders involved in these efforts is critical to their success.”

    The consortium now has eight launched projects and many others in development. At the meeting, Wholley will talk about a collaboration with the Predictive Safety Test Consortium (PSTC) of the Critical Path Institute to provide clinical qualification of multiple biomarkers of renal toxicity that PSTC had previously worked on with industry to qualify for use in preclinical phases of drug development.

    Wholley will also talk about the state of the field, and the role his consortium plays in it. The FNIH has been developing these kinds of biomedical research partnerships in support of the mission of the NIH for the past 12 years, but the Biomarkers Consortium is unique for providing an ongoing mechanism to develop a variety of projects of interest across multiple therapeutic areas.

    “Now, more than ever, there is a clear need for all participants in the biomedical research field to collaborate in the interest of moving the science forward, given the complexity of the research and current economic realities,” Wholley explains. “When managed appropriately, these kinds of public-private partnerships are a particularly effective mechanism for driving collaborations.”

  • Early Development

    Shaking up the drug pipeline means rethinking the way drugs are currently moving through the pipeline. “Confident, data-based decision making in early development of novel medicines is a critical capability in the pharmaceutical industry,” says Hans Winkler, Ph.D., senior director and global head, oncology biomarkers at Ortho Biotech Oncology Research and Development, a division of Janssen Pharmaceutica.

    “The way we are looking at handling early clinical trials now is that we have to study safety first and do those escalations as rapidly as possible in early cohorts where we are working on low doses and will collect only peripheral, noninvasive biomarker samples and not have mandatory tumor collection. Traditionally, we used to escalate dose until we established a maximal tolerated dose (MTD).”

    However, Dr. Winkler notes, with new targeted therapies, “we may not ever see a MTD, but we might actually have to rely on biological activity and we’re thinking it might be a biologically effective dose that will be the Phase II dose.”

    Once his group figures out a biologically effective dose, it will go into an expansion phase that will focus on specific tumor types, where the researchers believe that the target plays a controlling role. “We will test predictive markers to identify some populations, and in that focused population we will examine antitumor activity, looking at tumor cells pre- and post-treatment to make sure that we are giving the optimal dose.”

    The biggest challenge is getting tumor samples in early trials. “It’s not feasible to collect serial tumor biopsies, and the quality of biopsies is always an issue,” explains Dr. Winkler. “Logistics are still difficult, especially when it comes to larger trials. If you collect samples, you sometimes lose half of the samples in some way. We need to collect more like 80 to 90 percent usable samples.”

    For pharmacodynamic analysis, Dr. Winkler reports, “we need an early start and enough support to actually develop the assays to the degree that they are acceptable for clinical applications ahead of time. For predictive markers, we need to work up the assays to a point where we can actually test them in Phase II, we need to sort out the regulatory process, we need to have a strong hypothesis to be tested when we get into Phase II, and we need more predictive models to allow us to discover these predictive markers ahead of time, rather than in the clinic.”

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »